# 18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment

> **NCT02680041** · PHASE3 · COMPLETED · sponsor: **Blue Earth Diagnostics** · enrollment: 221 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 18F-fluciclovine PET CT

## Key facts

- **NCT ID:** NCT02680041
- **Lead sponsor:** Blue Earth Diagnostics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-01
- **Primary completion:** 2017-11-01
- **Final completion:** 2017-11-01
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2019-01-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02680041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02680041, "18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02680041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*